Lipid oxidation reprogramming in cancer-associated fibroblasts enhances CD8+ T cell cytotoxicity and therapeutic response

A study published in Cancer Cell by Ma et al. has identified a previously unrecognized subset of cancer-associated fibroblasts (CAFs) marked by PTGER3 expression that emerges in response to chemotherapy and exhibits elevated lipid oxidation. These specialized fibroblasts secrete the lipid mediator 11-HETE, which enhances CD8+ T cell killing capacity by suppressing PTEN-related signaling pathways within the T cells. Crucially, higher abundance of this PTGER3+ CAF population in patient tumors correlated with improved responses to therapy, suggesting these stromal cells actively support antitumor immunity. The findings reveal a novel and potentially targetable axis in the tumor microenvironment that links chemotherapy-induced stromal remodeling to immune activation. This work could inform future combination strategies that harness or amplify this protective fibroblast phenotype to boost immunotherapy efficacy.